Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Hopium Meeting Reality. Please click here for an enlarged chart of Hims & Hers Health Inc (HIMS). Note the following: In many ...

Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...

Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.